A cell therapy company launched by Syncona Ltd in 2019 has completed an oversubscribed Series B financing round to start the clinical development of a compound to prevent organ rejection in liver transplant patients. Quell Therapeutics Ltd raised $156 million from a consortia co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC. Syncona also participated in the round.
Quell is developing engineered T regulatory (Treg) cells as therapies.